$-0.07
(Market cap
$119 Mln
Recently Viewed
Clear AllMarket cap
$119 Mln
Revenue (TTM)
$190 Mln
P/E Ratio
--
P/B Ratio
23.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-24.4 %
ROCE
-- %
Industry P/E
52.92
EV/EBITDA
17.6
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
51,364,520
CFO
$-211.74 Mln
EBITDA
$-219.96 Mln
Net Profit
$-284.91 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
MDxHealth SA - ADR
| -38.0 | -29.9 | -46.6 | 38.4 | -61.8 | -- | -- |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
MDxHealth SA - ADR
| 50.6 | -39.6 | -94.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
MDxHealth SA - ADR
|
2.2 | 118.7 | 190.0 | -60.3 | -15.3 | -- | -- | 23.6 |
| 2.3 | 5.3 | 5.8 | -3.4 | -40.8 | -44 | -- | 0.6 | |
| 0.4 | 15.9 | 0.0 | -9.7 | -5,195.6 | -- | -- | 227.7 | |
| 0.1 | 2.1 | 0.0 | -2.6 | -17,715.7 | -- | -- | 38.3 | |
| 16.8 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that... measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company has a collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium. Read more
CEO & Executive Director
Mr. Michael K. McGarrity
CEO & Executive Director
Mr. Michael K. McGarrity
Headquarters
Herstal
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of MDxHealth SA - ADR is $2.22 (NASDAQ) as of 23-Apr-2026 11:34 EDT. MDxHealth SA - ADR has given a return of -61.76% in the last 3 years.
Since, TTM earnings of MDxHealth SA - ADR is negative, P/E ratio is not available.
The P/B ratio of MDxHealth SA - ADR is 23.64 times as on 17-Apr-2026, a 636 premium to its peers’ median range of 3.21 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-2.05
|
5.27
|
|
2023
|
-2.38
|
14.21
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of MDxHealth SA - ADR are Rs 5.33 and Rs 1.58 as of 23-Apr-2026.
MDxHealth SA - ADR has a market capitalisation of $ 119 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in MDxHealth SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.